Sagittal abdominal diameter is a more independent measure compared with waist circumference to predict arterial stiffness in subjects with type 2 diabetes - a prospective observational cohort study

Cardiovascular Diabetology

Volumn 12, Issue 1, 2013, Pages

  Dahlén, Elsa M ^a   Bjarnegård, Niclas ^a   Länne, Toste ^a   Nystrom, Fredrik H ^a,b   Östgren, Carl J ^a,b  

^a LINKÖPING UNIVERSITY   (Sweden)

^b LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Abdominal obesity; Atherosclerosis; Intima media thickness; Pulse wave velocity; Type 2 diabetes

Indexed keywords

ANTIHYPERTENSIVE AGENT; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; C REACTIVE PROTEIN; CHOLESTEROL; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ORAL ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ADULT; AGE; AGED; ANTHROPOMETRIC PARAMETERS; ANTIHYPERTENSIVE THERAPY; ARTERIAL STIFFNESS; ARTERIAL WALL THICKNESS; ARTICLE; BODY MASS; CAROTID ARTERY; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; DIABETES MELLITUS; DIABETIC PATIENT; DIASTOLIC BLOOD PRESSURE; FEMALE; FEMORAL ARTERY; FOLLOW UP; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; INTRAVASCULAR ULTRASOUND; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PROSPECTIVE STUDY; PULSE WAVE; RISK ASSESSMENT; SAGITTAL ABDOMINAL DIAMETER; SEX; SYSTOLIC BLOOD PRESSURE; TONOMETRY; WAIST CIRCUMFERENCE; ABDOMEN; ATHEROSCLEROSIS; BLOOD; BODY SIZE; COMPARATIVE STUDY; COMPLICATION; DIABETIC ANGIOPATHY; ECHOGRAPHY; INTRAABDOMINAL FAT; LONGITUDINAL STUDY; METABOLISM; MIDDLE AGED; OBESITY, ABDOMINAL;

ABDOMEN; AGED; APOLIPOPROTEINS B; ATHEROSCLEROSIS; BODY MASS INDEX; BODY SIZE; C-REACTIVE PROTEIN; CAROTID INTIMA-MEDIA THICKNESS; CHOLESTEROL, LDL; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INTRA-ABDOMINAL FAT; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; OBESITY, ABDOMINAL; PROSPECTIVE STUDIES; PULSE WAVE ANALYSIS; VASCULAR STIFFNESS; WAIST CIRCUMFERENCE;

EID: 84875359818     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-12-55     Document Type: Article

References (36)

1. Knowles KM, Paiva LL, Sanchez SE, Revilla L, Lopez T, Yasuda MB, Yanez ND, Gelaye B, Williams MA. Waist Circumference, Body Mass Index, and Other Measures of Adiposity in Predicting Cardiovascular Disease Risk Factors among Peruvian Adults. Int J Hypertens 2011, 2011:931402. 3034939, 21331161.
2. Petersson H, Daryani A, Riserus U. Sagittal abdominal diameter as a marker of inflammation and insulin resistance among immigrant women from the Middle East and native Swedish women: a cross-sectional study. Cardiovasc Diabetol 2007, 6:10. 10.1186/1475-2840-6-10, 1847804, 17391519.
3. Riserus U, Arnlov J, Brismar K, Zethelius B, Berglund L, Vessby B. Sagittal abdominal diameter is a strong anthropometric marker of insulin resistance and hyperproinsulinemia in obese men. Diabetes Care 2004, 27(8):2041-2046. 10.2337/diacare.27.8.2041, 15277437.
4. Gustat J, Elkasabany A, Srinivasan S, Berenson GS. Relation of abdominal height to cardiovascular risk factors in young adults: the Bogalusa heart study. Am J Epidemiol 2000, 151(9):885-891. 10.1093/oxfordjournals.aje.a010292, 10791561.
5. Ohrvall M, Berglund L, Vessby B. Sagittal abdominal diameter compared with other anthropometric measurements in relation to cardiovascular risk. Int J Obes Relat Metab Disord 2000, 24(4):497-501. 10.1038/sj.ijo.0801186, 10805508.
6. Kahn HS, Simoes EJ, Koponen M, Hanzlick R. The abdominal diameter index and sudden coronary death in men. Am J Cardiol 1996, 78(8):961-964. 10.1016/S0002-9149(96)00479-1, 8888678.
7. Seidell JC, Andres R, Sorkin JD, Muller DC. The sagittal waist diameter and mortality in men: the Baltimore Longitudinal Study on Aging. Int J Obes Relat Metab Disord 1994, 18(1):61-67.
8. Laakso M, Lehto S. Epidemiology of risk factors for cardiovascular disease in diabetes and impaired glucose tolerance. Atherosclerosis 1998, 137(Suppl):S65-S73.
9. Mehta S, Farmer JA. Obesity and inflammation: a new look at an old problem. Curr Atheroscler Rep 2007, 9(2):134-138. 10.1007/s11883-007-0009-4, 17877922.
10. Pickup JC, Mattock MB, Chusney GD, Burt D. NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 1997, 40(11):1286-1292. 10.1007/s001250050822, 9389420.
11. Kimberly MM, Cooper GR, Myers GL. An overview of inflammatory markers in type 2 diabetes from the perspective of the clinical chemist. Diabetes Technol Ther 2006, 8(1):37-44. 10.1089/dia.2006.8.37, 16472049.
12. Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation 2007, 115(4):459-467. 10.1161/CIRCULATIONAHA.106.628875, 17242284.
13. Lundby-Christensen L, Almdal TP, Carstensen B, Tarnow L, Wiinberg N. Carotid intima-media thickness in individuals with and without type 2 diabetes: a reproducibility study. Cardiovasc Diabetol 2010, 9:40. 10.1186/1475-2840-9-40, 2931499, 20727128.
14. Laurent S, Boutouyrie P. Arterial stiffness: a new surrogate end point for cardiovascular disease?. J Nephrol 2007, 20(Suppl 12):S45-S50.
15. Sutton-Tyrrell K, Najjar SS, Boudreau RM, Venkitachalam L, Kupelian V, Simonsick EM, Havlik R, Lakatta EG, Spurgeon H, Kritchevsky S. Elevated aortic pulse wave velocity, a marker of arterial stiffness, predicts cardiovascular events in well-functioning older adults. Circulation 2005, 111(25):3384-3390. 10.1161/CIRCULATIONAHA.104.483628, 15967850.
16. Wykretowicz A, Gerstenberger P, Guzik P, Milewska A, Krauze T, Adamska K, Rutkowska A, Wysocki H. Arterial stiffness in relation to subclinical atherosclerosis. Eur J Clin Invest 2009, 39(1):11-16. 10.1111/j.1365-2362.2008.02057.x, 19087126.
17. Dahlen EM, Lanne T, Engvall J, Lindstrom T, Grodzinsky E, Nystrom FH, Ostgren CJ. Carotid intima-media thickness and apolipoprotein B/apolipoprotein A-I ratio in middle-aged patients with Type 2 diabetes. Diabet Med 2009, 26(4):384-390. 10.1111/j.1464-5491.2009.02693.x, 19388968.
18. Wijkman M, Lanne T, Engvall J, Lindstrom T, Ostgren CJ, Nystrom FH. Masked nocturnal hypertension-a novel marker of risk in type 2 diabetes. Diabetologia 2009, 52(7):1258-1264. 10.1007/s00125-009-1369-9, 19396423.
19. Hoelzel W, Weykamp C, Jeppsson JO, Miedema K, Barr JR, Goodall I, Hoshino T, John WG, Kobold U, Little R. IFCC reference system for measurement of hemoglobin A1c in human blood and the national standardization schemes in the United States, Japan, and Sweden: a method-comparison study. Clin Chem 2004, 50(1):166-174. 10.1373/clinchem.2003.024802, 14709644.
20. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO, Criqui M, Fadl YY, Fortmann SP, Hong Y, Myers GL. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003, 107(3):499-511. 10.1161/01.CIR.0000052939.59093.45, 12551878.
21. van der Kooy K, Leenen R, Seidell JC, Deurenberg P, Visser M. Abdominal diameters as indicators of visceral fat: comparison between magnetic resonance imaging and anthropometry. Br J Nutr 1993, 70(1):47-58. 10.1079/BJN19930104, 8399118.
22. Clasey JL, Bouchard C, Teates CD, Riblett JE, Thorner MO, Hartman ML, Weltman A. The use of anthropometric and dual-energy X-ray absorptiometry (DXA) measures to estimate total abdominal and abdominal visceral fat in men and women. Obes Res 1999, 7(3):256-264. 10.1002/j.1550-8528.1999.tb00404.x, 10348496.
23. Pajunen P, Rissanen H, Laaksonen MA, Heliovaara M, Reunanen A, Knekt P. Sagittal Abdominal Diameter as a New Predictor for Incident Diabetes. Diabetes Care 2013, 36(2):283-288. 10.2337/dc11-2451, 22961578.
24. Despres JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature 2006, 444(7121):881-887. 10.1038/nature05488, 17167477.
25. Rittig K, Hieronimus A, Thamer C, Machann J, Peter A, Stock J, Schick F, Fritsche A, Stefan N, Haring HU. Reducing visceral adipose tissue mass is essential for improving endothelial function in type 2 diabetes prone individuals. Atherosclerosis 2010, 212(2):575-579. 10.1016/j.atherosclerosis.2010.06.042, 20667538.
26. Barnett KN, Ogston SA, McMurdo ME, Morris AD, Evans JM. A 12-year follow-up study of all-cause and cardiovascular mortality among 10,532 people newly diagnosed with Type 2 diabetes in Tayside, Scotland. Diabet Med 2010, 27(10):1124-1129. 10.1111/j.1464-5491.2010.03075.x, 20854379.
27. Nordhamn K, Sodergren E, Olsson E, Karlstrom B, Vessby B, Berglund L. Reliability of anthropometric measurements in overweight and lean subjects: consequences for correlations between anthropometric and other variables. Int J Obes Relat Metab Disord 2000, 24(5):652-657. 10.1038/sj.ijo.0801216, 10849590.
28. Ross R, Berentzen T, Bradshaw AJ, Janssen I, Kahn HS, Katzmarzyk PT, Kuk JL, Seidell JC, Snijder MB, Sorensen TI. Does the relationship between waist circumference, morbidity and mortality depend on measurement protocol for waist circumference?. Obes Rev 2008, 9(4):312-325. 10.1111/j.1467-789X.2007.00411.x, 17956544.
29. Brunzell JD, Davidson M, Furberg CD, Goldberg RB, Howard BV, Stein JH, Witztum JL. Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care 2008, 31(4):811-822. 10.2337/dc08-9018, 18375431.
30. Ryoo JH, Park SK. Association of apolipoprotein B and incidence of metabolic syndrome in Korean men: a 5-years' follow-up study. Atherosclerosis 2013, 226(2):496-501. 10.1016/j.atherosclerosis.2012.11.024, 23273962.
31. Cho DS, Woo S, Kim S, Byrne CD, Kong JH, Sung KC. Estimation of plasma apolipoprotein B concentration using routinely measured lipid biochemical tests in apparently healthy Asian adults. Cardiovasc Diabetol 2012, 11:55. 10.1186/1475-2840-11-55, 3458889, 22607125.
32. Holewijn S, Den Heijer M, Swinkels DW, Stalenhoef AF, De Graaf J. Apolipoprotein B, non-HDL cholesterol and LDL cholesterol for identifying individuals at increased cardiovascular risk. J Intern Med 2010, 268(6):567-577. 10.1111/j.1365-2796.2010.02277.x, 21091808.
33. Dehghan A, Van Hoek M, Sijbrands EJ, Stijnen T, Hofman A, Witteman JC. Risk of type 2 diabetes attributable to C-reactive protein and other risk factors. Diabetes Care 2007, 30(10):2695-2699. 10.2337/dc07-0348, 17623828.
34. An X, Yu D, Zhang R, Zhu J, Du R, Shi Y, Xiong X. Insulin resistance predicts progression of de novo atherosclerotic plaques in patients with coronary heart disease: a one-year follow-up study. Cardiovasc Diabetol 2012, 11:71. 10.1186/1475-2840-11-71, 3441242, 22709409.
35. Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 2001, 358(9298):2026-2033. 10.1016/S0140-6736(01)07098-2, 11755609.
36. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004, 364(9438):937-952. 10.1016/S0140-6736(04)17018-9, 15364185.